Peptide Library

FDA-approved

Brain & sleep

Trofinetide

Evidence

FDA approved

Class

Synthetic analog of an IGF-1 fragment

/

Trofinetide

KEY TAKEAWAY

Trofinetide is a small synthetic peptide based on a fragment of insulin-like growth factor 1 (IGF-1). It is sold as Daybue. The FDA approved trofinetide (Daybue) in March 2023 for Rett syndrome in adults and children aged 2 and older.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Synthetic analog of an IGF-1 fragment

Approved for

Rett syndrome in children and adults aged 2 and older

Key fact

The FDA approved trofinetide (Daybue) in March 2023 for Rett syndrome in adults and children aged 2 and older.

Route

Oral solution taken twice a day

Evidence strength

FDA approved

What it is

What it is

Trofinetide is a small synthetic peptide based on a fragment of insulin-like growth factor 1 (IGF-1). It is sold as Daybue.

How it works

How it works

It is thought to reduce inflammation and support the connections between nerve cells. How it helps in Rett syndrome is not fully understood.

Regulatory status

Regulatory status

The FDA approved trofinetide (Daybue) in March 2023 for Rett syndrome in adults and children aged 2 and older.

What it is used for

What it is used for

Rett syndrome in children and adults aged 2 and older.

Side effects and risks

Side effects and risks

Diarrhea and vomiting are the most common side effects. They can cause dehydration or weight loss in some people.

Citations

Citations

U.S. FDA prescribing information for Trofinetide. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo